Increased mortality in postmenopausal women with serum CA125 elevation

Gynecologic Oncology

Volumn 73, Issue 2, 1999, Pages 242-246

  Jeyarajah, Arjun R ^a   Ind, Thomas E J ^a   MacDonald, Nicola ^a   Skates, Steven ^b   Oram, David H ^a   Jacobs, Ian J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CA125 elevation; Mortality

Indexed keywords

CA 125 ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0032907245     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5350     Document Type: Article

References (25)

1. Rustin GJ, Nelstrop AE, Mclean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol 14(5):1545-1551, 1996
2. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE: Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group study. Ann Oncol 7(4):361-364, 1996
3. Ind TEJ, Iles R, Shepherd JH, Chard T: Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer. Br J Obstet Gynaecol 104:1024-1029, 1997
4. Jacobs IJ, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzinskas JG, Oram DH: Multimodal approach to screening for ovarian cancer. Lancet 1:268-271, 1988
5. Jacobs IJ, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram DH: Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. BMJ 306:1030-1034, 1993
6. Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyarajah AR, Weidemann P, Sibley K, Oram DH: Risk of diagnosis of ovarian cancer after raised serum CA125 concentration: a prospective cohort study. BMJ 313:1355-1358, 1996
7. Jacobs IJ, Bast RC: The CA125 tumour associated antigen; a review of the literature. Hum Reprod 4:1-12, 1989
8. Mantel N: Evaluation of survival data and two new rank order statistics arising in consideration. Cancer Chemother 50:163-170, 1966
9. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, Wiley, 1980
10. Office of National Statistics: Mortality Statistics by Cause for England and Wales 1996, Series DH2, No23, 1998
11. Einhorn N, Sjovall K, Knapp RC, Schoenfeld DA, Hall P, Eklund G: Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet Gynecol 80:14-18, 1992
12. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC: Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148(8):1057-1058, 1984
13. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB: Tissue distribution of a coelomic epithelium related antigen recognised by the monoclonal antibody OC125. Int J Gynecol Pathol 2(3):275-285, 1983
14. Yucel AE, Calguneri M, Ruacan S: False positive pleural biopsy and high CA125 levels in serum and pleural effusion in systemic lupus erythematosus. Clin Rheumatol 15(3):295-297, 1996
15. Penna L, Manyonda I, Amias A: Intra-abdominal miliary tuberculosis presenting as disseminated ovarian carcinoma with ascites and raised CA125. Br J Obstet Gynaecol 100(11):1051-1053, 1993
16. Kimura K, Ezoe K, Yokozeki H, Katayama I Nishioka K: Elevation of serum CA125 in progressive systemic sclerosis with pleural effusion. J Dermatol 22(1):28-31, 1995
17. Barbieri RL, Niloff JM, Bast RC, Schaetzl E, Kistner RW, Knapp RC: Elevated serum concentrations of CA125 in patients with advanced endometriosis. Fertil Steril 45(5):630-634, 1986
18. Kenemans P, Bast RC, Yedema CA, Price MR, Hilgers J: CA125 and polymorphic epithelial mucin as serum tumour markers. Cancer Rev 11-12:119-144, 1988
19. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M, Bensted J: The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and c-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol 6(6):581-587, 1995
20. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M, Bensted J: The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancers. Eur J Cancer 32A (1):63-68, 1996
21. Diez M, Gomez A, Hernando F, Ortega MD, Maestro ML, Torres A, Muguerza JM, Gutierrez A, Granell J, Balibrea JL: Serum CEA, CA125, and SCC antigens and tumour recurrence in resectable non-small-cell lung cancer. Int J Biol Markers 10(1):5-10, 1995
22. Kramer S, Raff U, Jager W, Lang N: CA125 as an indicator of pleural metastases in breast cancer. Anticancer Res 16(5B):3165-3168, 1996
23. Jeyarajah AR, Ind TEJ, Skates S, Oram DH, Jacobs IJ: Serum CA125 elevation and cancer risk in healthy postmenopausal women. Cancer (In Press).
24. Meier W, Stieber P, Hasholzner U, Gropp M, Fateh-Moghadam A: Prognostic significance of CA125 in patients with ovarian cancer and secondary debulking surgery. Anticancer Res 17(4B):2945-2947, 1997
25. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L: Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA125 in breast cancer patients at first relapse of disease. Eur J Cancer 30A(14):2082-2084, 1994